Traditional and newer pathologic factors.
There has long been a pressing clinical need to identify prognostic and predictive factors for patients with breast cancer. Although numerous candidate biological and molecular markers have been identified during the last two decades, traditional factors such as lymph node status, tumor size, histologic type, histologic grade, and hormone receptor status remain the most useful indicators of prognosis and therapeutic response. A major obstacle to the translation of research advances into clinically useful prognostic and predictive markers has been the considerable methodologic variability used in the evaluation of the newer markers. It is now generally accepted that, to be useful in patient management, a putative prognostic or predictive marker must have clinical importance, independence, significance, and standardization with regard to methods, interpretation, and reporting. It is hoped that recognition and adoption of these criteria will serve to clarify the value of newer biologic and molecular markers.
Schnitt
S J
SJ
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, East Campus, 330 Brookline Ave., Boston, MA 02215, USA. sschnitt@caregroup.harvard.edu
D015415:Biomarkers / Q000032:analysis; D001943:Breast Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology*; D018734:Genes, erbB-2 / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D008207:Lymphatic Metastasis; D018190:Neoplasm, Lymphatic Tissue / Q000503:physiopathology; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D015415:Biomarkers; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone